Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • Communities & Collections
  • Research Outputs
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. Faculty of Medicine
  4. Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anemia
 
  • Details
Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anemia
File(s)
Olupot-Olupot_P_2014_published.pdf (1.18 MB)
Published version
Author(s)
Olupot-Olupot, K
Engoru, C
Thompson, J
Nteziyaremye, J
Chebet, M
more
Type
Journal Article
Abstract
Background: Severe anemia (SA, hemoglobin <6 g/dl) is a leading cause of pediatric hospital admission in Africa,
with significant in-hospital mortality. The underlying etiology is often infectious, but specific pathogens are rarely
identified. Guidelines developed to encourage rational blood use recommend a standard volume of whole blood
(20 ml/kg) for transfusion, but this is commonly associated with a frequent need for repeat transfusion and poor
outcome. Evidence is lacking on what hemoglobin threshold criteria for intervention and volume are associated
with the optimal survival outcomes.
Methods: We evaluated the safety and efficacy of a higher volume of whole blood (30 ml/kg; Tx30: n = 78) against
the standard volume (20 ml/kg; Tx20: n = 82) in Ugandan children (median age 36 months (interquartile range
(IQR) 13 to 53)) for 24-hour anemia correction (hemoglobin >6 g/dl: primary outcome) and 28-day survival.
Results: Median admission hemoglobin was 4.2 g/dl (IQR 3.1 to 4.9). Initial volume received followed the
randomization strategy in 155 (97%) patients. By 24-hours, 70 (90%) children in the Tx30 arm had corrected SA
compared to 61 (74%) in the Tx20 arm; cause-specific hazard ratio = 1.54 (95% confidence interval 1.09 to 2.18, P = 0.01).
From admission to day 28 there was a greater hemoglobin increase from enrollment in Tx30 (global P <0.0001).
Serious adverse events included one non-fatal allergic reaction and one death in the Tx30 arm. There were six
deaths in the Tx20 arm (P = 0.12); three deaths were adjudicated as possibly related to transfusion, but none
secondary to volume overload.
Conclusion: A higher initial transfusion volume prescribed at hospital admission was safe and resulted in an
accelerated hematological recovery in Ugandan children with SA. Future testing in a large, pragmatic clinical
trial to establish the effect on short and longer-term survival is warranted.
Date Issued
2014-04-25
Date Acceptance
2014-03-17
Citation
BMC Medicine, 2014, 12
URI
http://hdl.handle.net/10044/1/28277
DOI
https://www.dx.doi.org/10.1186/1741-7015-12-67
ISSN
1741-7015
Publisher
BioMed Central
Journal / Book Title
BMC Medicine
Volume
12
Copyright Statement
© 2014 Olupot-Olupot et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
License URL
http://creativecommons.org/licenses/by/4.0/
Notes
source: Scopus
Publication Status
Published
Article Number
67
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback